AAM Statement on The Protecting Access to Affordable Medicines Act

WASHINGTON, D.C. (April 29, 2021) — “The Association for Accessible Medicines endorses The Protecting Access to Affordable Medicines Act, which helps ensure patients maintain uninterrupted access to low-cost medicines by fixing the misguided application of the Medicaid rebate to generic medicines.

We thank Representatives Butterfield (D-NC) and Long (R-MO) for introducing the act. We appreciate their work on behalf of patient access to generics and will work with them to advance this bipartisan legislation into law.”


Read Letter


Rachel Schwartz


About AAM

AAM is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 20 percent of total drug spending. 

About the Biosimilars Council

The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available at www.biosimilarscouncil.org.


Association for Accessible Medicines


Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.